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Metabolic syndrome is an important long term complication in chronic asymptom-
atic HIV-infected subjects under highly active antiretroviral therapy (HAART), be-
cause it can contribute to morbidity and mortality via cardiovascular disease 
(CVD). Therefore, a predictive marker for early detection of metabolic syndrome 
may be necessary to prevent CVD in HIV-infected subjects. Retinol-binding pro-
tein-4 (RBP-4) has been shown to be associated with metabolic syndrome in vari-
ous non-HIV-infected populations. We performed a cross-sectional study to evalu-
ate whether serum RBP-4 levels are correlated with metabolic syndrome in HIV-
infected subjects receiving HAART. In total, 98 HIV-infected Koreans who had 
been receiving HAART for at least 6 months were prospectively enrolled. Meta-
bolic syndrome was diagnosed according to the Adult Treatment Panel III criteria, 
and serum RBP-4 concentrations were measured using human RBP-4 sandwich en-
zyme-linked immunosorbent assay. Serum RBP-4 levels were significantly higher 
in HIV-infected subjects receiving HAART with metabolic syndrome (n=33, 
33.9±7.7 μg/mL) than in those without it (n=65, 29.9±7.2 μg/mL) (p=0.012). In 
multivariate linear regression analysis, the number of components of metabolic 
syndrome presented and waist circumference were independently, significantly 
correlated with RBP-4 (p=0.018 and 0.030, respectively). In conclusion, we re-
vealed a strong correlation between RBP-4 and the number of components of met-
abolic syndrome in HIV-infected subjects receiving HAART. 
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Highly active antiretroviral therapy (HAART) leads to a spectrum of metabolic 
complications, including lipodystrophy (LD), insulin resistance (IR) and dyslipid-
emia,1 that contribute to a higher prevalence of metabolic syndrome (MetSyn) and 
cardiovascular disease (CVD) in HIV-infected subjects.2-4 Therefore, early detec-
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patients who had ever taken anti-obesity medications, corti-
costeroids, peroxisome proliferator-activated receptor-gam-
ma (PPAR-γ) agonists, statins or fibrates, or had a history of 
diabetes mellitus or CVD. This study was approved by the 
Institutional Review Board of the Clinical Research Insti-
tute of Severance Hospital. Written informed consent was 
obtained from all participants. 
MetSyn was diagnosed according to the Adult Treatment 
Panel III criteria when three or more of the following five 
criteria were fulfilled: blood pressure (BP) >130/85 mm Hg 
or current use of anti-hypertensive drugs, fasting plasma 
glucose >110 mg/dL, high-density lipoprotein (HDL)-cho-
lesterol <40 mg/dL in men or <50 mg/dL in women, tri-
glyceride (TG) >150 mg/dL, and abdominal obesity (waist 
circumference >90 cm in men or >80 cm in women accord-
ing to the standards of the Asia-Pacific region).11,12 LD diag-
tion of MetSyn in these subjects may be important to pre-
venting CVD. Recent studies have reported that retinol-
binding protein-4 (RBP-4) is associated with IR,5,6 
dyslipidemia7 and obesity,8,9 as well as the components of 
MetSyn,6,7,9,10 in various non-HIV-infected populations. 
However, whether serum RBP-4 levels may serve as a risk 
marker for MetSyn in HIV-infected subjects has not been in-
vestigated. The aim of this study was to evaluate the associ-
ations between serum RBP-4 levels and MetSyn in HIV-in-
fected subjects receiving HAART.
A cross-sectional study was performed on 98 HIV-infect-
ed Koreans at Severance Hospital, Yonsei University Medi-
cal Center. We prospectively enrolled HIV-1-infected sub-
jects between March 2007 and March 2008. Patients were 
eligible if they were between 20 and 80 years old and had 
been receiving HAART for at least 6 months. We excluded 
Table 1. Characteristics of the Study Participants and Groups according to the Presence of Metabolic Syndrome
Variables Total (n=98) With MetSyn (n=33) Without MetSyn (n=65) p value
Age (yrs)   40.3±10.6   45.5±12.0 37.7±8.7 <0.001*
Gender, male 93 (94.9) 30 (90.9) 63 (96.9)   0.331†
No. of components of MetSyn   1.91±1.10   3.18±0.39   1.26±0.71 <0.001*
Components of MetSyn  
    Fasting glucose (mg/dL)         94.0 (87.0-109.0)        96.0 (91.0-112.0)        93.0 (84.0-104.0)   0.003‡
    HDL cholesterol (mg/dL)   46.8±10.9 40.7±7.8   49.6±11.0 <0.001*
    Triglyceride (mg/dL)   264.7±196.3   355.1±245.7   222.9±153.5   0.002*
    Systolic BP (mm Hg) 130.9±15.0 138.2±15.1 127.1±13.7 <0.001*
    Diastolic BP (mm Hg)   78.0±11.7   83.4±10.3   75.3±11.5   0.001*
    Waist circumference (cm) 82.5±7.4 86.3±8.1 80.5±6.2 <0.001*
Anthropometric parameters
    Weight (kg) 66.4±9.7   68.5±11.6 65.3±8.5   0.172*
    BMI (kg/m2) 22.6±2.7 23.8±2.9 22.0±2.4   0.002*
    WHR   0.88±0.06   0.90±0.05   0.86±0.06   0.001*
Lipodystrophy (yes) 30 (30.6) 15 (45.5) 15 (23.1)   0.041§
CD4+ T lymphocyte count ( /μL)   431.7±184.0   476.4±161.3   408.9±191.7   0.086*
Plasma HIV-RNA, undetectable|| 78 (79.6) 22 (71.0) 56 (83.6)   0.150§
RBP-4 (μg/mL) 31.20±7.56 33.87±7.72 29.85±7.15   0.012*
Total cholesterol (mg/dL) 186.7±42.0 196.0±38.9 182.4±42.9   0.198*
LDL cholesterol (mg/dL)   91.4±32.6   94.5±36.2   90.2±31.3   0.955*
Known duration of HIV infection (months)      27.0 (13.0-52.3)      30.0 (22.0-44.5)      27.0 (12.5-55.5)   0.715‡
Total duration of HAART (months)      19.0 (10.8-33.0)      24.0 (12.5-32.0)    18.0 (9.0-39.5)   0.291‡
MetSyn, metabolic syndrome; BP, blood pressure; BMI, body mass index; WHR, waist-to-hip ratio; HAART, highly active antiretroviral therapy; HDL, high-
density lipoprotein; RBP-4, retinol-binding protein-4; LDL, low-density lipoprotein.
Results are expressed as mean±SD, median (interquartile range) or n (%). 
Antiretroviral drugs which had been administered for at least 6 months until the measurement of serum RBP-4 levels [n (% of 98 subjects)]: nucleoside 
analogue reverse transcriptase inhibitor, zidovudine 43 (43.9), lamivudine 98 (100), stavudine 17 (17.3), didanosine 32 (32.7), abacavir 10 (10.2); non-nucle-
oside analogue reverse transcriptase inhibitor, efavirenz 30 (30.6); protease inhibitor, ritonavir-boosted lopinavir 50 (51.0), unboosted atazanavir 12 (12.2), 
unboosted nelfinavir 4 (4.1), unboosted indinavir 2 (2.0).
*Independent two sample t-test. 
†Fisher’s exact test. 
‡Mann-Whitney U test. 
§Pearson chi-square. 
||Less than 40 copies/mL. 
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13.0 software (SPSS Inc., Chicago, IL, USA). Data were 
expressed as means±SD, medians (interquartile range) or 
numbers (%). The two-tailed unpaired Student’s t-test or 
Mann-Whitney U test was used to compare the mean or 
median values of continuous variables. To analyze the dif-
ferences in nominal variables, we performed a chi-square 
test or Fisher’s exact test. To identify clinical parameters as-
sociated with RBP-4, a stepwise multivariate linear regres-
sion analysis was performed for age, BMI and all variables 
with a p-value of less than 0.10 on an age and BMI-adjust-
ed partial correlation analysis. p-values <0.05 were consid-
ered statistically significant. 
Thirty-three (33.7%) subjects fulfilled the criteria for Met-
Syn. The numbers of subjects per number of MetSyn com-
ponents presented, from 0 to 5, were 9, 25, 31, 18, 12 and 3 
in respective numerical order. The subjects with MetSyn 
were older and had significantly higher BMI and WHR than 
subjects without MetSyn. The percentage of patients with 
LD was higher in the group with MetSyn (45.5% vs. 23.1%, 
p=0.041). Also, serum RBP-4 level was significantly higher 
in subjects with MetSyn (33.87±7.72 vs. 29.85±7.15 μg/mL, 
p=0.012) (Table 1).
nosis was based on the clinical definition set by the US Di-
vision of AIDS adverse events (2004 version), in addition 
to a standardized LD-specific physical examination con-
ducted by a single clinician and a previously described LD-
specific questionnaire completed by the patient.13 BP, height, 
weight, and waist and hip circumference were measured. 
Waist-to-hip ratio (WHR) and body mass index (BMI) were 
also calculated. 
We obtained blood samples following a 12-hour over-
night fast. Plasma glucose, total cholesterol, triglyceride, 
HDL-cholesterol, peripheral blood CD4+ T lymphocyte 
counts, and plasma HIV-RNA were measured using stan-
dard laboratory methods. Low-density lipoprotein-choles-
terol was calculated using the Friedewald formula,14 except 
in patients with TG levels higher than 400 mg/dL. 
Serum RBP-4 concentrations were measured using the 
commercially available human RBP-4 sandwich enzyme-
linked immunosorbent assay kit (Immunodiagnostik AG, 
Bensheim, Germany). The assay was conducted according 
to the manufacturer’s instructions. The inter-assay and intra-
assay variations were 9.8% and 5%, respectively.
All statistical analyses were performed using the SPSS 
Table 2. Correlation between Serum RBP-4 Levels and Covariates
Variables
Serum RBP-4
Univariate analysis Stepwise multivariate linear 
regression analysis*Unadjusted Age and BMI adjusted
Univariate correlation 
coefficient
p value
Partial correlation 
coefficient
p value
Standardized 
regression coefficient
p value
No. of components of MetSyn   0.357 <0.001 0.251 0.015 0.252 0.018
Log [fasting glucose (mg/dL)]†   0.069 0.502 0.057 0.582 NI -
HDL cholesterol (mg/dL) -0.187 0.065 -0.159 0.125 NI -
Triglyceride (mg/dL)   0.270 0.007 0.219 0.034 EX -
Systolic BP (mm Hg)   0.185 0.069 0.127 0.221 NI -
Diastolic BP (mm Hg)   0.089 0.385 0.053 0.615 NI -
Waist circumference (cm)   0.338 0.001 0.228 0.027 0.231 0.030
WHR   0.237 0.020 0.133 0.206 NI -
BMI (kg/m2)   0.230 0.024 - - EX -
Total cholesterol (mg/dL)   0.135 0.184 0.029 0.783 NI -
LDL cholesterol (mg/dL) -0.018 0.862 -0.108 0.302 NI -
Log [total duration of HAART   
  (months)]†
-0.020 0.843 0.011 0.912 NI -
Log [known duration of HIV 
  infection (months)]†
-0.034 0.740 -0.035 0.739 NI -
MetSyn, metabolic syndrome; BP, blood pressure; WHR, waist-to-hip ratio; BMI, body mass index; HAART, highly active antiretroviral therapy; NI, not in-
cluded in the multivariate model; EX, excluded variables in the multivariate model; RBP-4, retinol-binding protein-4; HDL, high-density lipoprotein; LDL, low-
density lipoprotein.
*Independent variables included in the multivariate model were age, BMI and all variables with a p-value of less than 0.10 on an age and BMI-adjusted 
partial correlation analysis. In this model, the cut-off level of the probability of F value used for the entry or removal of successively entered variables was 
0.05 and 0.10, respectively. 
†Logarithmic transformation was performed because of a skewed distribution. 
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ed with a higher risk of MetSyn in HIV-infected subjects 
receiving HAART. We also found a strong correlation be-
tween serum RBP-4 levels and the number of components 
of MetSyn, in particular, its key components, including TG 
and waist circumference. This significant correlation was 
not attenuated after adjustment for age and BMI, which are 
known to be related to the prevalence of MetSyn.18,19 We 
also noted an increased prevalence of LD in HIV-infected 
subjects with MetSyn. These findings suggest a potential 
role for serum RBP-4 as a diagnostic marker for early de-
tection of metabolic complications in HIV-infected subjects 
receiving HAART. To our knowledge, this is the first study 
to evaluate the relationship between serum RBP-4 levels 
and the presence of MetSyn in HIV-infected subjects. How-
ever, we did not compare serum RBP-4 levels between HIV-
infected subjects receiving HAART without MetSyn and 
non-HIV-infected healthy individuals without MetSyn, in 
this study. In addition, we did not measure serum RBP-4 
levels in the HIV-infected individuals who have never re-
ceived HAART (treatment-naïve individuals). Therefore, 
there may be the possibility that neither HIV infection itself 
nor HAART have any impact on the association between 
RBP-4 and MetSyn. Further study with the aforementioned 
study design and a larger sample set is needed to evaluate 
whether serum RBP-4 levels are useful as diagnostic markers 
for MetSyn and/or predictive factors for the development of 
MetSyn or CVD in HIV-infected subjects receiving HAART, 
as well as to reveal the exact mechanism or causality for the 
relationship between RBP-4 and MetSyn in HIV-infected 
subjects. Because serum RBP-4 levels may be a useful mark-
er for MetSyn and the measurement of serum RBP-4 levels 
is not difficult, it could allow clinicians and scientists to read-
ily collect valuable information on metabolic complications 
in HIV-infected subjects receiving HAART. 
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